卫光生物：收到药品注册临床试验受理通知书

Core Viewpoint - The company has received a clinical trial application acceptance notice from the National Medical Products Administration for its subcutaneous human immunoglobulin product, indicating progress in its drug development pipeline [1] Group 1: Product Information - The drug is named subcutaneous human immunoglobulin, with a specification of 2g/bottle (20%, 10ml) [1] - It is classified as a Class 3.2 therapeutic biological product [1] - The drug is indicated for primary immunodeficiency diseases (PID), including X-linked agammaglobulinemia, common variable immunodeficiency, and immunoglobulin G subclass deficiency [1]